TY - JOUR

T1 - Prognose og behandling af nonalkoholisk fedtleversygdom og steatohepatitis

AU - Heebøll, Sara

AU - Kazankov, Konstantin

AU - Poulsen, Marianne Kjær

AU - Vilstrup, Hendrik

AU - Grønbæk, Henning

PY - 2012

Y1 - 2012

N2 - Non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) are among the most common liver diseases. NAFLD with pure steatosis is considered benign. NASH, however, may progress to liver cirrhosis with risk of liver cancer. Therefore, it is important to search for treatment modalities for NASH. Because obesity and insulin resistance are risk factors for NASH, weight loss and exercise are considered mandatory, although limited data are in support. Presently, we focus on the prognosis of NAFLD and NASH and on pharmaceutical treatment, especially in the form of vitamin E and pioglitazone.

AB - Non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) are among the most common liver diseases. NAFLD with pure steatosis is considered benign. NASH, however, may progress to liver cirrhosis with risk of liver cancer. Therefore, it is important to search for treatment modalities for NASH. Because obesity and insulin resistance are risk factors for NASH, weight loss and exercise are considered mandatory, although limited data are in support. Presently, we focus on the prognosis of NAFLD and NASH and on pharmaceutical treatment, especially in the form of vitamin E and pioglitazone.

M3 - Review

C2 - 22348670

VL - 174

SP - 488

EP - 490

JO - Ugeskrift for Læger

JF - Ugeskrift for Læger

SN - 0041-5782

IS - 8

ER -